ICBII Update on the Road to the Cure - November 2022

A Real-Time Science Report
Ram S. Bhatt, PhD., Chief Science Officer

Fibroblast Growth Factor 1 (FGF-1) - Scientists at Zhittya Genesis Medicine are looking at fibroblast growth factor 1 (FGF-1) as a potential medicine to cure Parkinson’s disease. The rationale behind the use of FGF-1 to treat PARKINSON’S is solid because it is a well-known potent stimulator of new blood vessels and is capable of growing new blood vessels in the ischemic area of the body, including the brain. Lack of blood flow to dopamine producing neurons in the substantia nigra appears to be one of the reasons for the death of dopaminergic neurons leading to the classic symptoms of Parkinson’s. Therefore, growing new blood vessels in the substantia should help Parkinson’s patients.

Zhittya Genesis Medicine claims that FGF-1 has shown excellent efficacy in treating Parkinson’s disease in Cynomolgus monkeys. Parkinson’s monkeys were generated by injecting the pesticide neurotoxin, MPTP, in the brain. This neurotoxin selectively destroys dopamine producing neurons in the substantia nigra producing classical symptoms of Parkinson’s disease in animals. After one group of monkeys was administered FGF-1 and the other a placebo dose, the FGF-1 administered (intracranial injection) monkeys not only improved their motor scores almost to normal, but also increased their dopamine production and decreased their buildup of alpha-synuclein plaque.

Administering Difficulty – FGF-1 is a large protein with a molecular weight of about 18 kDa. It is not blood-brain barrier (BBB) permeable. Intracranial injections are not only invasive but also have the risk of serious side effects. In addition, such mode of treatment will limit the use of FGF-1 for treating Parkinson’s only to a selected few rich individuals as it will require a hospital stay. Therefore, alternative non-invasive strategies to administer FGF-1 will be needed, if indeed this is a curative drug.

Good News: ICB International, Inc, has the technology to transport FGF-1 to the brain.

ADDITIONALLY, WOULD YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of these historical events can be had by helping ICBII find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact ICBII directly through their website ICBII.com or by phone 858-455-9880.

IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease.

JUST IMAGINE.